The management of Irvine-Gass Syndrome in a patient using Inhaler Steroid
International Journal of Clinical and Experimental Ophthalmology · 2018
DOI: 10.29328/journal.ijceo.1001011 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical and Experimental Ophthalmology, 2018. Verfasst von Ayse Gul Kocak Altintas und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Irvine-Gass syndrome, is one of the most common causes of painless decrease in vision following even uneventful cataract surgery. It usually responds well to medical therapy, but, there are no widely acceptedconsensus on the efficacy of various therapeutic options for the treatment of Irvine-Gass syndrome. The patient presenting in this case report, has systemic hypertension and chronic obstructive pulmonary disease and he use oral anti-hypertension medication and inhaler steroid. He diagnosed as Irvine-Gass syndrome due to presence of decrease in visual acuity and macular edema with hyporeflective cystic intraretinal spaces in optical coherence tomography (OCT) since4th weekcontrol visitfollowing uneventful cataract surgery. After the responsiveness of several medications including topical steroid and non-steroidal anti-inflammatory drugs and intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF), intravitreal sustained-release dexamethasone implant was applied. The visual acuity improved to 0.00 logMAR at 1st month after intravitreal dexamethasone therapy and consecutive OCT images showed complete resolution of macular edema with a normalization of the foveal profile.The visual acuity and foveal architecture remained stable in 2-year follow-up period and additional treatment was not needed. To the best of our knowledge, this is the first reportthatmentions the increment of visual acuity after a single dexamethasone implant, even though it did not response anti-VEGF combined with topical steroid and non-steroidal anti-inflammatory drugs.
Zitieren
APA
Altintas, A. G. K., Ilhan, C., & Citirik, M. (2018). The management of Irvine-Gass Syndrome in a patient using Inhaler Steroid. International Journal of Clinical and Experimental Ophthalmology. https://doi.org/10.29328/journal.ijceo.1001011
Vancouver
Altintas AGK, Ilhan C, Citirik M. The management of Irvine-Gass Syndrome in a patient using Inhaler Steroid. International Journal of Clinical and Experimental Ophthalmology. 2018. doi:10.29328/journal.ijceo.1001011
BibTeX
@article{Altintas2018,
author = {Altintas, Ayse Gul Kocak and Ilhan, Cagri and Citirik, Mehmet},
title = {The management of Irvine-Gass Syndrome in a patient using Inhaler Steroid},
journal = {International Journal of Clinical and Experimental Ophthalmology},
year = {2018},
doi = {10.29328/journal.ijceo.1001011}
}
EUVIMED